NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.

The deal, which will run for one year with the option to extend to two, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. While Compugen would not disclose financial details of the arrangement, a company spokesperson revealed that it was in the “multi-million dollar per year” range.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.